Moderna's AI Could Get a Hantavirus Vaccine Here Faster

Drug development has always been a slow business. A single medicine can take 10 to 15 years and cost billions before it reaches a patient.

PYMNTS • 13 hours ago

Moderna's Revenues See Strong International Momentum in Q1 Earnings

MRNA's Q1 revenues soar 260% on strong international vaccine sales, while cost cuts and new EU approvals support its broader growth strategy.

Zacks Investment Research • 16 hours ago

Moderna, Inc. (MRNA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Moderna, Inc. (MRNA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • 9 hours ago

Moderna Recognized by TIME as One of the World's Most Impactful Companies

CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies.

Accesswire • 9 hours ago

Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging.

Moderna's stock is rallying on hopes it could develop a hantavirus vaccine.

Investopedia • May 12, 2026

Moderna stock soars as hantavirus fears spark outbreak trade

Moderna shares surged on Monday as investors rushed into vaccine and biotech stocks following reports of a hantavirus outbreak linked to a cruise ship, despite health authorities maintaining that the overall public health risk remains low. The stock rose 9.43% to $59.48, its intraday high after a US national tested mildly positive for the Andes strain of hantavirus.

Invezz • May 11, 2026

Moderna shares extend gains as hantavirus vaccine work draws attention

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) shares continued to extend recent gains on Monday as investors welcomed reports that the company is researching a hantavirus vaccine and advancing early-stage work in the area. Shares of Moderna have added more than 16% in the last five days, trading hands at about $55.

Proactive Investors • May 11, 2026

Moderna Shares Surge On Hantavirus Concerns: What Investors Need To Know

Moderna Inc (NASDAQ:MRNA) shares are trading higher during Monday's pre-market session as investors focus shifts to an emerging global health concern, a hantavirus outbreak, that has highlighted the company's specialized research pipeline. Here's what investors need to know.

Benzinga • May 11, 2026

Here's how much Moderna's stock has rallied off renewed focus on hantavirus research

The public is growing increasingly concerned about the possibility that a hantavirus outbreak on a cruise could spark a new pandemic.

Market Watch • May 11, 2026

Hantavirus cases spark surge in pharma and biotech stocks — here's why

Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.

CNBC • May 11, 2026